阿立哌唑治疗精神分裂症的临床研究

Clinical analysis of Aripiprazole in the treatment of schizophrenia

目的:评价阿立哌唑治疗精神分裂症的疗效及不良反应。方法:将64例精神分裂症患者随机分为两组,分别给予阿立哌唑与利培酮治疗8周。采用阳性与阴性症状量表(PANSS)、治疗中出现的症状量表(TESS)评定疗效及不良反应。结果:阿立哌唑组显效率78.1%,利培酮组为75.0%,两组疗效比较差别无统计学意义(P<0.05)。利培酮组锥体外系反应稍高于阿立哌唑组。结论:阿立哌唑与利培酮疗效相似,锥体外系反应比利培酮少,是有效、安全的抗精神病药物。

Objective： To observe the adverse events and efficacy of Aripiprazole in the treatment of schizophrenia. Methods： Sixty - four cases of schizophrenia were randomly divided into Aripiprazole group and Risperidone group. The course of treatments was 8 weeks. The therapeutic effects were evaluated by positive and negative symptom scale （PANSS） ,and side effects were assessed by treatment emergent symptom scale （TESS）. Results：The rates of marked improvement in Aripiprazole group and Risperidone group were 78.1% and 75.0% respectively. The extractor - ticospinal （EPS） tract re- action was more severe in fisperidone group than in Aripiprazole group. Conclusion： Afipiprazole, as well as Risperidone,is one of effective antipsychotics and less EPS in the treatment of schizophrenia.